Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.
You may also be interested in...
Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.
Califf’s Trial Design Prescription: Less Randomization, More Transparency
FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.